Dexcom Inc (Dexcom) designs, develops and commercializes continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and healthcare providers in the hospital for the treatment of diabetes. Its major products include Dexcom G6 CGM system, Dexcom Share and Dexcom Clarity diabetes management software. Dexom’s G6 is a real time, CGM device indicated for the management of diabetes in persons’ aged two years and older.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Dexcom’s R&D efforts focused on enhancing its current CGM products and to develop next generation CGM products, technologies, and services internally and through strategic collaboration with its partners. The primary focus of its research and development efforts is on developing continuous glucose monitoring technology, clinical trials, quality assurance programs, and the procurement of materials and products for clinical trials. It conducts R&D activities at its facility in San Diego, California, the US. In FY2022, it spent US$484.2 million on its R&D activities, which as a percentage of revenue stood at 17%.